Literature DB >> 7246447

Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs.

J H Jentzer, T H Lejemtel, E H Sonnenblick, E S Kirk.   

Abstract

In 11 dogs ischemic left ventricular failure characterized by a 30 percent reduction in cardiac output and a left ventricular end-diastolic pressure of 18 mm Hg or more was produced by proximal occlusion of the left anterior descending coronary artery followed by serial occlusions of the distal left circumflex coronary artery. Administration of amrinone in an intravenous bolus injection followed by a constant infusion produced improvements in cardiac output (from 1.62 +/- 0.50 to 2.19 +/- 0.52 liters/min [mean +/- standard deviation], p less than 0.05), left ventricular end-diastolic pressure (from 21.6 +/- 3.5 to 11.0 +/- 5.4 mm Hg, p less than 0.05) and peak positive rate of rise of left ventricular pressure [dP/dt] (from 1,264 +/- 241 to 1,800 +/- 458 mm Hg.s-1, p less than 0.05). These improvements were maintained throughout the 20 minute period of therapy. No significant alteration in heart rate or arterial pressure was noted. In parallel with the hemodynamic improvement myocardial oxygen consumption improved to 0.094 +/- 0.05 and 0.092 +/- 0.04 vol.min-1.g-1 after 2 and 20 minutes, respectively, of amrinone compared with 0.124 +/- 0.05 during left ventricular failure (both p less than 0.05). The effects of amrinone on left ventricular failure are due to augmented contractility and mild systemic vasodilatation. The reduction in myocardial oxygen consumption during amrinone-treated left ventricular failure presumably results from a reduction in ventricular wall tension that more than offsets the effect of an increase in contractility.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7246447     DOI: 10.1016/0002-9149(81)90574-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts.

Authors:  A F Rump; D Acar; W Klaus
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

2.  Amrinone improves postischemic myocardial metabolism in the rat heart-lung preparation.

Authors:  Masaki Kume; Satoshi Kashimoto; Atsusi Furuya; Teruo Kumazawa
Journal:  J Anesth       Date:  1996-12       Impact factor: 2.078

Review 3.  Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors.

Authors:  M Schlepper; J Thormann; V Mitrovic
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

4.  Use of milrinone in the management of haemodynamic instability following duct ligation.

Authors:  Arvind Sehgal; Johny V Francis; Anthony I Lewis
Journal:  Eur J Pediatr       Date:  2010-09-17       Impact factor: 3.183

5.  Electrophysiological effects of amrinone on the automaticity and membrane current system of the rabbit sinoatrial node cells.

Authors:  T Hata; M Nishimura; K Ogino; H Uchiyama; Y Watanabe
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

6.  Influence of heart rate on the effects of prenalterol on regional myocardial blood flow and function during coronary stenosis in dogs.

Authors:  A Berdeaux; C Bonhenry; P Duhazé; J F Giudicelli; C Thuillez
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

Review 7.  Amrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-12       Impact factor: 9.546

8.  Free radical scavenging properties of beta-adrenoceptor blockers are not relevant for cardioprotection in isolated rabbit hearts.

Authors:  A F Rump; R Rösen; W Klaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.